Bull Market Won't B...
Health Care: Drugs
Protalix BioTherapeutics Inc. (PLX: AMEX)
$5.21 0.01 | 0.19%
05/21/13 - 04:03 PM ET
Portfolios with PLX
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- UserSharebuilder
- UserSUPRATRADE HOT STOCKS (BUY ...
- Usergilver Portfolio 1
- UserTop Biotech Short Squeeze P...
- UserEdwin Lee Portfolio 1
Latest PLX Headlines from TheStreet
- 5 Stocks Under $10 Set to Soar 04.04.13 | 01:04 pm
- Protalix BioTherapeutics Treats First Gaucher Patient In Phase I Study With PRX-112, An Orally-Administered Enzyme Treatment Of Gaucher Disease 04.02.13 | 07:04 am
- UPLYSO(TM) (alfataliglicerase) Approved In Brazil By ANVISA For The Treatment Of Gaucher Disease 03.18.13 | 02:03 pm
- Protalix BioTherapeutics Receives Approval To Initiate Phase I Study In Gaucher Patients With PRX-112, An Orally-Administered Candidate For The Treatment Of Gaucher Disease 03.07.13 | 08:03 am
- Protalix Announces New Clinical Data On ELELYSO(TM) To Be Presented At The WORLD Symposium 2013 02.13.13 | 07:02 am
- Protalix BioTherapeutics Reviewing Partnering And Other Alternatives 02.05.13 | 11:02 am
- Protalix BioTherapeutics To Present At The 15th Annual BIO CEO & Investor Conference 02.05.13 | 07:02 am
- Protalix BioTherapeutics Announces New Clinical Data On Taliglucerase Alfa To Be Presented At The WORLD Lysosomal Disease Network Symposium 01.31.13 | 07:01 am
- Protalix BioTherapeutics Announces First Patient Treated In Phase I/II Study Of Fabry Patients With PRX-102 12.10.12 | 02:12 am
- 4 Plays Under $10 on the Rise 11.13.12 | 05:11 pm
Press Releases for PLX
- Pfizer And Protalix BioTherapeutics Announce FDA Approval Of ELELYSO™ (taliglucerase Alfa) For The Treatment Of Gaucher Disease - Business Wire 05.01.12 | 06:05 pm
- FDA Extends Taliglucerase Alfa PDUFA Date To May 1, 2012 - PR Newswire 12.06.11 | 07:12 am
- Protalix Announces Successful European GMP Audit - PR Newswire 12.01.11 | 02:12 am
- Protalix's Acetylcholinesterase Demonstrates Potential Role In The Treatment Of Parkinson's Disease - PR Newswire 11.10.11 | 01:11 am
- Protalix BioTherapeutics To Present At Four Upcoming Conferences - PR Newswire 10.26.11 | 07:10 am
- Protalix BioTherapeutics To Present At The Jefferies 2011 Global Healthcare Conference - PR Newswire 09.21.11 | 07:09 am
- Protalix BioTherapeutics To Present At The UBS Global Life Sciences Conference - PR Newswire 09.13.11 | 08:09 am
- Protalix BioTherapeutics' Taliglucerase Alfa Phase III Results Published In Blood, The Journal Of The American Society Of Hematology - PR Newswire 09.08.11 | 08:09 am
- Protalix BioTherapeutics Announces FDA Accepts For Review Complete Response Resubmission For Taliglucerase Alfa And Assigns PDUFA Date - PR Newswire 08.17.11 | 07:08 am
- Protalix Submits Reply To FDA Complete Response Letter For Taliglucerase Alfa And Reports Top-Line Results From The Company's Switchover Trial - PR Newswire 08.01.11 | 08:08 am
Partner Headlines for PLX
- Orphan Status Sought for PSTI Drug - Analyst Blog - NASDAQ 08.31.12 | 09:08 pm
- Pluristem to Begin IC Phase II Trial - Analyst Blog - NASDAQ 08.24.12 | 10:08 pm
- Pluristem-BCRT Alliance Extended - Analyst Blog - NASDAQ 08.22.12 | 11:08 pm
- Pluristem Gets Green Light in India - Analyst Blog - NASDAQ 08.20.12 | 11:08 pm
- Medgenics Moving In Record Time - Seeking Alpha 05.21.12 | 09:05 am
- 6 Biotech Stocks With Huge Potential In May - Seeking Alpha 04.11.12 | 08:04 am
- Protalix Reinforces Case For Taliglucerase Alfa; Healthcare Sector Volume Keeps Rising - Seeking Alpha 02.10.12 | 08:02 am
- Company News for December 7, 2011 - Corporate Summary - Zacks 12.07.11 | 09:12 am
- Protalix BioTherapeutics: FDA Delay Provides Attractive Entry Point - Seeking Alpha 12.07.11 | 09:12 am
- Morning Market Losers - Benzinga 12.06.11 | 09:12 am
